Salomon Tendler

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

Salomon Tendler, Mark Dunphy, Matthew Agee et al. · The Lancet Oncology · 2024 · 49 citations · Full text

Medicine, Oncology, Radiology +16

Treatment patterns and survival outcomes for small-cell lung cancer patients – a Swedish single center cohort study

Salomon Tendler, Yiqiang Zhan, Andreas Pettersson et al. · Acta Oncologica · 2020 · 33 citations · Full text

Medicine, Oncology, Chemotherapy +15

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy

Salomon Tendler, Lena Kanter, Rolf Lewensohn et al. · PLoS ONE · 2020 · 29 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden

Salomon Tendler, Vitali Grozman, Rolf Lewensohn et al. · Lung Cancer · 2018 · 24 citations

Medicine, Oncology, Pathology +11

Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study

Salomon Tendler, Marit Holmqvist, Gunnar Wagenius et al. · Lung Cancer · 2019 · 12 citations

Medicine, Medical Education, Oncology +8